434 participants
Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2025-11-13
- Start Date:
- 2020-07-21
- Completion:
- 2022-06-23
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
- DRUG